2023 Research Articles

Related

• Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation  PMID: 36822371 
  Summary: "In patients with chronic constipation, the vibrating capsule was superior to placebo in improving bowel symptoms and quality of life. The vibrating capsule was safe and well tolerated.”
  
• Vibrant - an oral vibrating capsule for chronic idiopathic constipation  PMID: 37155248
• The Gut Microbial Bile Acid Modulation and its Relevance to Digestive Health and Diseases  PMID: 36841488
• Associations between postprandial symptoms, hydrogen and methane production, and transit time in irritable bowel syndrome  PMID: 36221245
• DUODENAL LUMINAL MICROBIOME PROFILES EXHIBIT SEX-SPECIFIC DIFFERENCES
• Coronavirus Disease 2019 (COVID-19) Pandemic Lifestyle Changes May Have Influenced Small Bowel Microbial Composition and Microbial Resistance  PMID: 37578565
• Management of Chronic Constipation: A Comprehensive Review.  PMID: 37952945
• Consuming artificial sweeteners may alter the structure and function of duodenal microbial communities  PMID: 38125028

Overview

• Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO  PMID: 36985147
• Small Intestinal Bacterial Overgrowth PMID: 31536241
• Small Intestinal Bacterial Overgrowth  PMID: 31536241
• Unravelling the controversy with small intestinal bacterial overgrowth  PMID: 37144539  
• Small intestinal bacterial overgrowth: current update.  PMID: 37751393
• Small intestinal bacterial overgrowth. A position paper of ASENEM-SEPD.  PMID: 37982553

Causes/ Risk Factors 
 Altered Anatomy

• Diffuse Jejunal Lipomatosis and Associated Complications.  PMID: 37860810 NEW 
  

Drugs/medication

• Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care PMID: 36943203
• Decongestants, proton pump inhibitors, and systemic antibiotics are associated with an increased occurrence of dysbiosis PMID: 36594656
  
• Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics PMID: 37142877
  
• Incidence of Small Intestinal Bacterial Overgrowth and Symptoms After 7 Days of Proton Pump Inhibitor Use: A Study on Healthy Volunteers.  PMID: 37910339. 
  Summary: After a short 7-day course of PPI’s in healthy asymptomatic subjects, 7.8% developed SIBO (>90% did not develop SIBO). Note: Common parameters of PPI’s use are different than in this study: PPI’s are often taken longer than 7 days and by those with GI symptoms.​
  

Surgery

• Chronic loose stools following right-sided hemicolectomy for colon cancer and the association with bile acid malabsorption and small intestinal bacterial overgrowth  PMID: 36347822
  
• The Prevalence of Small Intestinal Bacterial Overgrowth After Roux-en-Y Gastric Bypass (RYGB): a Systematic Review and Meta-analysis.  PMID: 38062344
  

​Pathophysiology

• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome PMID: 36573834
• Altered gut microbiota in patients with small intestinal bacterial overgrowth  PMID: 36180941
• The small intestine: dining table of host-microbiota meetings PMID: 37193669
• Defining Small Intestinal Bacterial Overgrowth by Culture and High Throughput Sequencing  PMID: 37315761
• Clinical Presentation of Small Intestinal Bacterial Overgrowth from Aerodigestive Tract Bacteria Versus Colonic-Type Bacteria: A Comparison Study  PMID: 37322103
• IMPORTANCE OF METHANOGENS IN IBS: ASSOCIATIONS WITH SYMPTOMS, TRANSIT TIME, AND BREATH METHANE AND HYDROGEN PRODUCTION
• ARCHAEA HAVE DIFFERENTIAL EFFECTS ON SYMPTOMS AND THE MICROBIOME THAT DEPEND ON METHANOGENIC COMPOSITION AND GI TRACT LOCATION
• THE FIRST LUMINAL SHOTGUN SEQUENCING OF THE SMALL INTESTINE IDENTIFIES SPECIFIC STRAINS OF ESCHERICHIA AND KLEBSIELLA IN SIBO WHICH ARE LINKED TO GASTROINTESTINAL SYMPTOM SEVERITY.
  
• TRANSCRIPTOMICS IN SIBO PATIENTS REVEALS THE IMPORTANCE OF KLEBSIELLA IN DYSREGULATION OF GENE EXPRESSION ASSOCIATED WITH GUT IMMUNITY AND MOTILITY
• DYSBIOSIS INDUCED BY CDTB TOXIN PROMOTES CHANGES IN MICRORNA EXPRESSION THAT MODULATE EXPRESSION OF GENES ASSOCIATED WITH GUT MOTILITY, BARRIER FUNCTION AND PAIN
• BREATH TEST RESULTS IN IBS-D SUBJECTS ARE ASSOCIATED WITH DIFFERING BOWEL MOVEMENT MORPHOLOGY DETECTED BY ARTIFICIAL INTELLIGENCE
  
• Hydrogen Sulfide Producers Drive a Diarrhea-Like Phenotype and a Methane Producer Drives a Constipation-Like Phenotype in Animal Models.  PMID: 38060167
  Summary: “…increased M. smithii levels result in a constipation-like phenotype in a rat model that is partly reversible with methanogenesis inhibitors, whereas gavage with H2S producers D. piger or F. varium results in increased colonization with other H2S producers [particularly Lachnospiraceae and Bilophila in F. varium-gavaged rats, and Sutterella in D. piger-gavaged rats], and diarrhea-like phenotypes. This supports roles for the increased RA of methanogens and H2S producers identified in IBS-C and IBS-D subjects, respectively, in contributing to stool phenotypes.”
  
• Cytolethal distending toxin B inoculation leads to distinct gut microtypes and IBS-D-like microRNA-mediated gene expression changes in a rodent mode  PMID: 38108386
  Summary: This article investigates the pathophysiology of IBS-Diarrhea type/SIBO hydrogen and hydrogen sulfide type, caused by food poisoning (the most common cause of SIBO). The study exposed rats to CdtB toxin (the toxin released in bacterial food poisoning).
  • Three small intestine (ileal) types were found (“microtypes”).
    • Microbiome diversity was reduced in the type associated with hydrogen SIBO but increased in the type associated with hydrogen sulfide SIBO.
    • E. coli was increased in the hydrogen type
    • Parasutterella and Desulfovibrio were increased in the hydrogen sulfide type
    • The third type was similar to controls but with some microbiome changes
    • Leaky gut markers were found in all three types.
  • Alterations included:
    • Leaky gut markers
    • Inflammation (via LPS and cytokines TNFα, IL2, IL5, IL18)
    • Microbiome changes
    • Diarrhea-like stool
      
    • Visceral hypersensitivity/pain genes associated with IBS were affected
    • Gastrointestinal motility genes associated with IBS were affected
  • CdtB exposure (bacterial food poisoning) results in IBS
• Exploring the Small Intestinal Microbiome: Relationships to Symptoms and Small Intestinal Bacterial Overgrowth.  PMID: 37797906
  

Associated Conditions
Celiac Disease

• Celiac disease in Chilean adults doi.org/10.1016/j.rgmxen.2022.03.007
• Transition of Care in Celiac Disease  PMID: 37273133
• Transition of Care in Celiac Disease.  PMID: 37273133

Children (Pediatric)

• Prevalence, risk factors, and treatment of small intestinal bacterial overgrowth in children  PMID: 37599259

Cholangitis

• The prevalence and impact of small intestine bacterial overgrowth in biliary atresia patients PMID: 37726543
  

Chronic Intestinal Pseudo-Obstruction

• Pharmacological and nutritional therapy of children and adults with chronic intestinal pseudo-obstruction  PMID: 36939480

​Covid-19

• SIBO: the trail of a new human pathology associated with multiple severe and disabling Covid-19 and long Covid symptoms or induced by the anti-Covid-19 vaccine  PMID: 36762752
• Post-COVID-19 Gastro-Intestinal Disturbances PMID: 36464877

Critically Ill ICU patients NEW

• High Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in ICU Patients: An Observational Study  PMID: 37489018​
  

Cystic Fibrosis

• Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract in Cystic Fibrosis.  PMID: 38057499
  

Ehlers-Danlos syndrome

• Low prevalence of positive hydrogen breath tests in patients with functional gastrointestinal conditions and hypermobile Ehlers-Danlos syndrome PMID: 36989174
• The spectrum of gastrointestinal functional bowel disorders in joint hypermobility syndrome and in an academic referral center.  PMID: 37858959

H. pylori

• Helicobacter pylori infection and small intestinal bacterial overgrowth: a systematic review and meta-analysis.  PMID: 38053022
  Summary: This meta-analysis found that H. pylori infection is related to a higher odds (OR 1.82) of SIBO in adults under 48 years old, and not related to those over 48 years old, or exposure to proton pump inhibitors. Testing for SIBO in adults with H. pylori infection is advised. 
  

​Hypothyroidism (Subclinical)

• Probiotics and Prebiotics in Subclinical Hypothyroidism of Pregnancy with Small Intestinal Bacterial Overgrowth  PMID: 37032411

IBD

• Impact of Small Intestinal Bacterial Overgrowth in Patients with Inflammatory Bowel Disease and Other Gastrointestinal Disorders-A Retrospective Analysis in a Tertiary Single Center and Review of the Literature PMID: 36769583
• The Impact of Confounders on Symptom-Endoscopic Discordances in Crohn's Disease  PMID: 37016720
  
• Impact of small intestinal bacterial overgrowth on symptoms and quality of life in irritable bowel syndrome  PMID: 37200005

IBS

• Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology PMID: 36961659
• Irritable bowel syndrome - controversies in diagnosis and management PMID: 37317843
• Prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome (IBS): Correlating H2 or CH4 production with severity of IBS  PMID: 37125253

Gallbladder Polyps 

• Small Intestinal Bacterial Overgrowth in Patients with Gallbladder Polyps: A Cross-Sectional Study PMID: 36883124

Lactose Intolerance

• Lactase Deficiency Diagnosed by Endoscopic Biopsy-based Method is Associated With Positivity to Glucose Breath Test PMID: 36606439
• Efficacy of incremental loads of cow's milk as a treatment for lactose malabsorption in Japan PMID: 36818633

Lipomatosis NEW

• Diffuse Jejunal Lipomatosis and Associated Complications.  PMID: 37860810

Liver Disease

• Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023? PMID: 36986052
• Gut-Microbiota Dysbiosis in Stroke-Prone Spontaneously Hypertensive Rats with Diet-Induced Steatohepatitis  PMID: 36902037
• Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in Patients with Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis: A Cross-Sectional Study PMID: 36985296
• Small Intestinal Bacterial Overgrowth Is Associated with Poor Prognosis in Cirrhosis  PMID: 37110440
• Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota  PMID: 37545638
• Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease.  PMID: 37834367
• Changes of the bacterial composition in duodenal fluid from patients with liver cirrhosis and molecular bacterascites  PMID: 38155157

​MCAS

• Complex Presentations, Identification and Treatment of Mast Cell Activation Syndrome and Associated Conditions: A Case Report.  PMID: 3775293
  

Obesity

• The role of small intestinal bacterial overgrowth in obesity and its related diseases  PMID: 37044299

​Pancreatitis (acute)

• Characterization of Duodenal Microbiota in Patients with Acute Pancreatitis and Healthy Controls PMID: 37258979

Parkinson’s disease

• Berlin Bowel Bothers: Might Adolf Hitler's Gut Problems Have Been Parkinson-Related? PMID: 36921591
• The Role of Helicobacter pylori and Small Intestinal Bacterial Overgrowth in Parkinson's Disease  PMID: 37562451
• Gut-Brain Axis a Key Player to Control Gut Dysbiosis in Neurological Diseases.  PMID: 37851313 

Short Bowel Syndrome

• Gut Microbiota Modulation of Short Bowel Syndrome and the Gut-Brain Axis  PMID: 37299543
• An Overview of Short-Bowel Syndrome in Pediatric Patients: Focus on Clinical Management and Prevention of Complications  PMID: 37242224
• Short bowel syndrome: Complications and management PMID: 37115034
• Nutritional and medical approaches to intestinal failure PMID: 37017713

Small Intestinal Fungal Overgrowth (SIFO)

• INCREASED FUNGAL LOADS DETECTED IN DUODENAL ASPIRATES USING MULTIPLEXED DIGITAL POLYMERASE CHAIN REACTION ARE ASSOCIATED WITH MORE SEVERE UPPER RESPIRATORY SYMPTOMS AND ABDOMINAL PAIN

Stroke 

• Risk factors for small intestinal bacterial overgrowth in patients with acute ischaemic stroke  PMID: 36762525
  Summary: "The prevalence of SIBO in patients with AIS (acute ischemic stroke) was 28.8 %. TG (triglycerides) and Hcy (homocysteine) levels are independent risk factors for SIBO in patients with AIS. Both markers had good predictive value for the occurrence of SIBO.” 
  

Systemic Sclerosis

• A Phenome-Wide Association Study of Drugs and Comorbidities Associated With Gastrointestinal Dysfunction in Systemic Sclerosis PMID: 36792109
• Small Intestinal Bacterial Overgrowth Complicating Gastrointestinal Manifestations of Systemic Sclerosis: A Systematic Review and Meta-analysis PMID: 37019859
• Antivinculin Antibodies in Systemic Sclerosis: Associations With Slow Gastric Transit and Extraintestinal Clinical Phenotype  doi/10.1002/acr.25118

Testing

• Evaluation of small intestinal bacterial overgrowth  PMID: 37088924
• Unravelling the controversy with small intestinal bacterial overgrowth  PMID: 37144539
• Content validation of a daily patient-reported outcome measure for assessing symptoms in patients with Small Intestinal Bacterial Overgrowth  PMID: 37212941
• Defining Small Intestinal Bacterial Overgrowth by Culture and High Throughput Sequencing  PMID: 37315761
• INCREASED COLIFORMS IN THE SMALL BOWEL ARE A SIGNATURE OF PATIENTS WITH SIBO AND PROFOUNDLY IMPACT THE LUMINAL RESIDENT MICROBIAL COMMUNITY
• SMALL INTESTINAL BACTERIAL OVERGROWTH AS ASSESSED BY AN INGESTIBLE GAS SENSING DEVICE: A PROSPECTIVE COMPARISON TO BOTH ASPIRATE AND BREATH TESTING
• NOVEL REAL-TIME ASSESSMENT OF ENDOGENOUS AND EXOGENOUS VOLATILE ORGANIC COMPOUNDS (VOCS) ON BREATH IN HEALTHY SUBJECTS – NEXT GENERATION BIOMARKER DEVELOPMENT FOR DIGESTIVE HEALTH.
• Small Intestinal Bacterial Overgrowths and Intestinal Methanogen Overgrowths Breath Testing in a Real-Life French Cohort  PMID: 36515897
• Understanding Our Tests: Hydrogen-Methane Breath Testing to Diagnose Small Intestinal Bacterial Overgrowth  PMID: 36744854
• BREATH TEST RESULTS IN IBS-D SUBJECTS ARE ASSOCIATED WITH DIFFERING BOWEL MOVEMENT MORPHOLOGY DETECTED BY ARTIFICIAL INTELLIGENCE
• PORTABLE HYDROGEN BREATH TEST (H2) CORRELATES WITH INGESTION OF FODMAP CONTAINING FOODS
• Plasma levels of intestinal Fatty-Acid Binding protein (I-FABP), abdominal distension and hydrogen concentration after lactitol SIBO test PMID: 36926907
• UNDERSTANDING OUR TESTS: HYDROGEN-METHANE BREATH TESTING TO DIAGNOSE SMALL INTESTINAL BACTERIAL OVERGROWTH PMID: 36744854
• Comparison of jejunal aspirate culture and methane and hydrogen breath test in the diagnosis of small intestinal bacterial overgrowth. PMID: 37725319
• AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review  PMID: 37452811
• Does Single Fasting Methane Levels Really Detect Intestinal Methanogen Overgrowth?  PMID: 37377266
• Photoacoustic Spectroscopy-Based Breath Analysis for SIBO.  PMID: 38085692
• [Single hydrogen-methane breath test for the diagnosis of small intestinal bacterial growth].  PMID: 37935501

Methane

• Prevalence of methanogens and associated factors in patients with irritable bowel syndrome and healthy controls in a Southeastern Mexican population  PMID: 34863643
• Antibiotics inhibit methanogenesis during municipal solid waste decomposition. PMID: 37758143 
  Summary: This study tested antibiotics against methane fermentation in sewage sludge and found that "Metronidazole, AMO [Amoxicillin] and CIP [Ciprofloxacin] exerted the most significant effect on the fermentation process". Metronidazole had the most potent effect, which makes sense since it is a key methane treatment. Neomycin (another key methane treatment) wasn't tested.
  
• In vitro interactions between Blautia hydrogenotrophica, Desulfovibrio piger and Methanobrevibacter smithii under hydrogenotrophic conditions.  PMID: 37753963
• Maternal Consumption of Non-Nutritive Sweeteners during Pregnancy Is Associated with Alterations in the Colostrum Microbiota.  PMID: 38068786 
  Summary: This study analyzed breastmilk colostrum microbes in mothers consuming non-nutritive sweeteners (NNS). “…A significant increase in the unclassified archaea Methanobrevibacter spp. was observed as the consumption frequency of NNS increased. … NNS consumption during pregnancy could be related to changes in colostrum microbiota and may affect infants' gut microbiota seeding and their future health.”
  

Hydrogen Sulfide

• Desulfovibrio in the Gut: The Enemy within?  PMID: 37512944
• Chemistry of Hydrogen Sulfide-Pathological and Physiological Functions in Mammalian Cells.  PMID: 38067112

​Treatment

• Diagnosis by Microbial Culture, Breath Tests and Urinary Excretion Tests, and Treatments of Small Intestinal Bacterial Overgrowth PMID: 36830173
• Efficacy and Safety of Pea Protein and Xyloglucan Versus Simethicone in Functional Abdominal Bloating and Distension.  PMID: 37923826

Acupuncture

• The efficacy and neural mechanism of acupuncture therapy in the treatment of visceral hypersensitivity in irritable bowel syndrome  PMID: 37732301​

Antibiotics

• The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.  PMID: 37971270
• Rifaximin Prevents Intestinal Barrier Dysfunction and Alleviates Liver Injury in MCT-induced HSOS Mice.  PMID: 37950130
• Distinct Effects of Non-absorbed Agents Rifaximin and Berberine on the Microbiota-Gut-Brain Axis in Dysbiosis-induced Visceral Hypersensitivity in Rats.  PMID: 37814439
• Neomycin.  PMID: 32809438
• Berberine protects against neomycin-induced ototoxicity by reducing ROS generation and activating the PI3K/AKT pathway.  PMID: 37844727

Antibiotics: Rifaximin

• Efficacies of prokinetics and rifaximin on the positivity of a glucose breath test in patients with functional dyspepsia: a randomized trial  PMID: 35748472
• Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice PMID: 36658488​

Chinese Herbs​

• Relationship among Chinese herb polysaccharide (CHP), gut microbiota, and chronic diarrhea and impact of CHP on chronic diarrhea.  PMID: 37823142

Herbal Antibiotics 

• Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study) PMID: 36873985
• Distinct Effects of Non-absorbed Agents Rifaximin and Berberine on the Microbiota-Gut-Brain Axis in Dysbiosis-induced Visceral Hypersensitivity in Rats.  PMID: 37814439
• Berberine protects against neomycin-induced ototoxicity by reducing ROS generation and activating the PI3K/AKT pathway.  PMID: 37844727

Probiotics

• "Impact of Saccharomyces boulardii CNCM I-745 on bacterial overgrowth and composition of intestinal microbiota in IBS-D patients: results of a randomized pilot study"  PMID: 36630947
  Summary: "In patients with SIBO, S. boulardii CNCM I-745, associated with dietary advice, reduced bacterial overgrowth and improved digestive symptoms while restoring the intestinal microbiota....The safety of S. boulardii was excellent. "
• ​Probiotics and Prebiotics in Subclinical Hypothyroidism of Pregnancy with Small Intestinal Bacterial Overgrowth  PMID: 37032411
• Probiotic Formulations Containing Fixed and Essential Oils Ameliorates SIBO-Induced Gut Dysbiosis in Rats  PMID: 37513952 
  Study Conclusions: "This study observed that the important role of probiotics in ameliorating SIBO is further enhanced by their combination with oil. ...Coconut oil + trace amounts of peppermint-lemon-patchouli essential oil and a probiotic mixture. ... rats treated with the oil plus probiotic mix protocol recovered from digestive system defects caused by dysbiosis. Reproducing these results with well-designed prospective clinical trials will pave the way for the introduction of probiotics into routine clinical use in SIBO."

Prokinetics

• Efficacies of prokinetics and rifaximin on the positivity of a glucose breath test in patients with functional dyspepsia: a randomized trial  PMID: 35748472
• A Review of the Cardiovascular Safety of Prucalopride in Patients with Chronic Idiopathic Constipation PMID: 3692795 Summary: "In a real-world European CV (cardiovascular) safety study among 35,087 patients ... results were consistent for no evidence of increased risk of major adverse CV events among patients treated with prucalopride vs PEG3350. Studies to date have not raised concerns regarding the impact of prucalopride treatment on CV parameters."
• Tissue distribution and abuse potential of prucalopride: findings from non-clinical and clinical studies PMID: 36876155
• Effectiveness of electroacupuncture versus prucalopride for women with severe chronic constipation: secondary analysis of a randomized controlled trial PMID: 36662303
• ​5-HT4 Receptor Agonist Effects on Functional Connectivity in the Human Brain: Implications for Procognitive Action PMID: 37098409
  Summary: Low dose Prucalopride (commonly used for prevention of SIBO relapse), was shown to have procognitive effects (helps memory, learning and cognitive tasks) via it’s 5-HT4 receptor effects.
  
• THE HERBAL PREPARATION, STW5-II, RELAXES THE PROXIMAL STOMACH, AND STIMULATES ANTRAL AND PYLORIC CONTRACTILITY, IN HEALTHY HUMANS [STW5-II is Iberogast®, commonly used in SIBO treatment, minus 3 herbs (milk thistle, angelica,celandine)]
• Safety and effectiveness of traditional herbal medicine Siho-sogan-san in functional dyspepsia: A systematic review and meta-analysis  PMID: 37127143
• Use of gastrointestinal prokinetics and the risk of parkinsonism: A population-based case-crossover study.  PMID: 37491627
• Impact of Erythromycin as a Prokinetic on the Gut Microbiome in Children with Feeding Intolerance-A Pilot Study.  PMID: 37998808
  Summary: “Stool samples from pediatric patients with feeding intolerance who received EES [erythromycin x 12 weeks] as a prokinetic, were analyzed for both bacteriome and mycobiome. …the relative abundance and prevalence of many fungal genera were significantly higher in the EES group [erythromycin] when compared to the controls. … Candida dominated. …Generally, the commensal bacteria predominate in gut microbiota and mitigate the fungal overgrowth and invasive fungemia [70]. When the bacteria are perturbed by antibacterial antibiotics, opportunistic fungal (especially Candida) growth may increase.”
  

​Rifaximin

• Rifaximin PMID: 32966000
• Update on the Role of Rifaximin in Digestive Diseases PMID: 37004222
• Efficacy of Rifaximin in Patients With Abdominal Bloating or Distension: A Systematic Review and Meta-analysis  PMID: 37310270
• Antibiotics and Probiotics for Irritable Bowel Syndrome  PMID: 37184752

Diet: FODMAP

• PSYCHOLOGICAL VARIABLES AND ILLNESS PERCEPTIONS PREDICT SYMPTOM RESPONSE WITH THE LOW FODMAP DIET: A 6-MONTH LONGITUDINAL STUDY IN ADULTS WITH IRRITABLE BOWEL SYNDROME
• A MULTICENTER RANDOMIZED CONTROLLED TRIAL OF MICROBIOME-BASED ARTIFICIAL INTELLIGENCE-ASSISTED PERSONALIZED DIET VS FODMAP DIET: A NOVEL PERSONALIZED THERAPEUTIC APPROACH FOR IBS
• FECAL LPS CAUSES FODMAP-MEDIATED BARRIER DYSFUNCTION IN IBS-D VIA TLR4-DEPENDENT MAST-CELL ACTIVATION
• The low FODMAP diet in clinical practice: where are we and what are the long-term considerations?  PMID: 37415490
• Existing differences between available lists of FODMAP-containing foods  PMID: 35100806
• A Low FODMAP Diet Is Better Than an Oral Spasmolytic for Irritable Bowel Syndrome  PMID: 37590868
• Optimizing educational methods for the low FODMAP diet in disorders of gut-brain interaction: A feasibility randomized controlled trial  PMID: 37480191
• Diet and Management of Diarrhea  PMID: 37480452
• Evaluation of the effects of the FODMAP diet and probiotics on irritable bowel syndrome (IBS) symptoms, quality of life and depression in women with IBS  PMID: 37430435
• Impact of different fibre ingredients on a low-FODMAP biscuit model system  PMID: 37455535
• Nutrition Considerations in Patients with Functional Diarrhea  PMID: 37329427
• Detection of changes in regional colonic fermentation in response to supplementing a low FODMAP diet with dietary fibres by hydrogen concentrations, but not by luminal pH  PMID: 37386938
• The Impact of a 24-h Low and High Fermentable Oligo- Di- Mono-Saccharides and Polyol (FODMAP) Diet on Plasma Bacterial Profile in Response to Exertional-Heat Stress  PMID: 37571312
• Does sourdough bread provide clinically relevant health benefits?  PMID: 37545587
• FACTORS ASSOCIATED WITH ADHERENCE TO A LOW FERMENTABLE CARBOHYDRATE DIET IN CHILDREN WITH FUNCTIONAL GASTROINTESTINAL DISORDERS  PMID: 37683726
• Effects of FODMAPs and Gluten on Gut Microbiota and Their Association with the Metabolome in Irritable Bowel Syndrome: A Double-Blind, Randomized, Cross-Over Intervention Study  PMID: 37447371
• Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols diet is associated with increased risk of uninvestigated chronic dyspepsia and its symptoms in adults  PMID: 33971708
• The Effects of Agave Fructans in a Functional Food Consumed by Patients with Irritable Bowel Syndrome with Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial  PMID: 37630717
• "Non-Allergic Diseases Associated with Foods".  PMID: 37783385
• FODMAP meal challenge test: a novel investigation to predict response to low-FODMAP diet in non-constipating irritable bowel syndrome. PMID: 38014751
• A dietitian-led low-FODMAP diet webinar: a pre-post study evaluating its impact on symptoms of irritable bowel syndrome.  PMID: 37905715
• Unlocking the potential of low FODMAPs sourdough technology for management of irritable bowel syndrome.  PMID: 37803764
• The Long-Term Effects of a Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet for Irritable Bowel Syndrome Management.  PMID: 37807975
• Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review.  PMID: 38021264
• Spot Hydrogen Breath Test for Predicting Response to Low Fermentable Oligo-, Di-, Mono-saccharides, and Polyols Dietary Advice in Patients With Bloating.  PMID: 37814438
• Case Report: Initial Successful Treatment of Migraine and Irritable Bowel Syndrome With a Low-FODMAP Diet  PMID: 38108544